



Presented by

[CEO] João Balancho

[CTO] Pedro Duarte

[CFO] Vasco Mota

problems

1

Mass Disposal

230 Milion CGM sensors
are used and discorded
annually

[2025]

2

Limited Lifespan

Majority of sensor only
lasts 7 to 14 days

3


High Replacement Cost

Each sensor costs on
average 60€ per unit

4


Enzyme Dependence

Current glucose sensors rely
on fragile enzymatic
chemistry, limiting stability
and increasing cost




Industry Leaders

Abbott (FreeStyle Libre), Dexcom, Medtronic, Senseonics



People with Diabetes

Numbering over 800 million, as of 2022, published by the World Health Organization



Healthcare Systems Insurance Companies

Interested in reducing costs of treating diabetes complications

CUSTOMERS

[2025]

Competitors



Abbott

Enzymatic, minimally invasive sensor replaced every 14 days, affordable but disposable, with no wireless charging or

reuse

[2025]



Enzymatic CGM with Bluetooth connectivity, replaced every 10–14 days, enzyme degradation over time



Senseonics

Implantable enzymatic sensor lasting up to 180 days, requires minor surgery and manual recharge every 24–48h



SugarBEAT

Daily-wear patch CGM using electrical signals, non-invasive but requires new patch each day.

OUR SOLUTION

1

CUSTOM ASIC CHIP

We are developing a custom ASIC chip to integrate into next-generation glucose sensors:

2

NON-ENZYMATIC

More stable, longer lifespan

3

WIRELESS CHARGING

No disposable batteries

4

NON-INVASIVE

More comfortable and reusable

5

BATTERY LIFE

Extend the sensor's useful life


6

LOW COST

Dramatically reduce cost and e-waste

[2025]

BLOCK DIAGRAMS



[2025]

competitive Advantages

Enzyme-free Detection

More stable over time, no biochemical degradation → higher accuracy & lower recalibration need.

Wireless Charging Integration

No disposable batteries, enables multi week continuous operation.

Extended Device Lifetime


Designed for use beyond 180 days, reduces medical e-waste and user replacement burden.

Lower Long-term Cost per User

ASIC SoC reduces bill-of-material, less frequent replacements = reduced cost for users and healthcare systems

[2025]

Solution sustainability




TECHNOLOGICAL

Proprietary, patentable ASIC for use in systems with **enzyme-free architectures**.

Designed for **long lifespan, low power, and wireless charging**.

Scalable to different sensing platforms.



OPERATIONAL

Fabless model → low cost, fast scaling.
Uses **standard CMOS nodes**, lowering cost and ensuring supply.

Built for high-volume, low-waste manufacturing.



STRATEGIC

We **integrate with existing CGM players**, not compete with them.


Strong potential for **OEM partnerships** and clinical/regulatory alliances.

Lean business model with high-margin licensing

[2025]

ASIC Sales

Sell pre-fabricated SoCs to sensor companies, margin on chip production.



IP Licensing

Licensing IP for various modules used in our ASIC with recurring royalties per IP sold.



Customization

Services

Offer integration, tuning and support for specific use-cases, one-time engineering fees.



Long-Term SaaS

Potential

Enable device-cloud integration with analytics tools, open path to subscription revenue from B2B clients.




how to make money

[2025]

Organizational Plan


- Headcount scales with growth



[2025]

Financial Plan

- Break-even in Year 2 and rapid profitability thereafter
- Net profit climbs to €16.5M by Year 5



[2025]

our partnerships

1
2

Seed funding

ASIC final design & tape-out
(via TSMC or GlobalFoundries),
regulatory pre-certification &
prototyping

Technical team

Analog/RF engineers, PMIC
designer, firmware & BLE
developer.

OEM partnerships

Secure 2–3 pilot agreements
with CGM manufacturers,
early licensing or
co-development deals.

Manufacturing & packaging partners

Fabless supply chain (IC
foundry + OSAT provider),
packaging for medical
integration.

Regulatory & clinical support


Clinical validation to ensure
compliance (e.g., FDA, CE
Mark) and med-tech partner
to manage trials

[2025]



thanks!

Q&A



Presented by

[CEO] João Balancho

[CTO] Pedro Duarte

[CFO] Vasco Mota